WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H326916
CAS#: 112856-44-7
Description: Losigamone, also known as AO-33; ADD-137022, is GABA receptor agonist potentially for the treatment of partial seizures.
Hodoodo Cat#: H326916
Name: Losigamone
CAS#: 112856-44-7
Chemical Formula: C12H11ClO4
Exact Mass: 254.03
Molecular Weight: 254.666
Elemental Analysis: C, 56.60; H, 4.35; Cl, 13.92; O, 25.13
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: AO-33; AO 33; AO33; ADD-137022; ADD 137022; ADD137022; Losigamone
IUPAC/Chemical Name: (5R*)-5-((alphaS*)-o-Chloro-alpha-hydroxybenzyl)-4-methoxy-2(5H)-furanone
InChi Key: ICDNYWJQGWNLFP-RYUDHWBXSA-N
InChi Code: InChI=1S/C12H11ClO4/c1-16-9-6-10(14)17-12(9)11(15)7-4-2-3-5-8(7)13/h2-6,11-12,15H,1H3/t11-,12-/m0/s1
SMILES Code: O=C1O[C@H]([C@@H](O)C2=CC=CC=C2Cl)C(OC)=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 254.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Willmore LJ. Losigamone. Dr Willmar Schwabe. Curr Opin Investig Drugs. 2001
Dec;2(12):1763-6. Review. PubMed PMID: 11892943.
2: Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic
drugs. Focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet. 1996
Jul;31(1):29-46. Review. PubMed PMID: 8827398.
3: Biber A, Dienel A. Pharmacokinetics of losigamone, a new antiepileptic drug,
in healthy male volunteers. Int J Clin Pharmacol Ther. 1996 Jan;34(1):6-11.
PubMed PMID: 8688997.
4: Dimpfel W, Chatterjee SS, Nöldner M, Ticku MK. Effects of the anticonvulsant
losigamone and its isomers on the GABAA receptor system. Epilepsia. 1995
Oct;36(10):983-9. PubMed PMID: 7555962.